目的 探討消癌平注射液聯(lián)合欖香烯注射液治療中晚期原發(fā)性肝癌的臨床療效。方法 選取2014年1月-2015年9月在蘄春縣人民醫(yī)院接受治療的中晚期原發(fā)性肝癌患者82例,按照治療方法的差別分成對照組和治療組,每組各41例,對照組患者靜脈滴注欖香烯注射液,0.6g加入5%葡萄糖溶液500mL,1次/d。治療組在對照組基礎上靜脈滴注消癌平注射液,40mL加入5%葡萄糖溶液250mL,1次/d。兩組患者均連續(xù)治療2個療程,其中3周為1個療程,休息1周后進行下1個療程治療。觀察兩組近期臨床療效和生存質量改善率,比較兩組CD³⁺、CD⁴⁺和CD⁴⁺/CD⁸⁺淋巴細胞水平變化,并對比兩組治療前后血清MMP-2和MMP-9水平的變化。結果 治療后,對照組客觀緩解率(ORR)43.90%,臨床獲益率(CBR)75.61%,治療組客觀緩解率(ORR)65.85%,臨床獲益率(CBR)92.68%,兩組ORR、CBR比較差異有統(tǒng)計學意義(P<0.05);對照組與治療組生存質量改善率分別為80.49%、95.12%,兩組比較差異具有統(tǒng)計學意義(P<0.05);兩組患者CD³⁺、CD⁴⁺、CD⁴⁺/CD⁸⁺均較治療前明顯增高,同組治療前后差異具有統(tǒng)計學意義(P<0.05),但治療組增高更明顯,與對照組相比差異具有統(tǒng)計學意義(P<0.05);兩組血清MMP-2和MMP-9水平均比同組治療前明顯降低,差異具有統(tǒng)計學意義(P<0.05),治療組降低的更顯著,與對照組相比差異具有統(tǒng)計學意義(P<0.05)。結論 消癌平注射液聯(lián)合欖香烯注射液治療中晚期原發(fā)性肝癌具有良好的臨床療效,安全性高,具有一定的臨床推廣應用價值。

ObjectiveTo investigate the clinical effect and safety of Xiaoaiping Injection combined with Elemene Injection in treatment of advanced primary hepatocellular carcinoma. Methods Patients (82 cases) with advanced primary hepatocellular carcinoma in Qichun People's Hospital from January 2014 to September 2015 were divided into control and treatment groups, each group had 41 cases. Patients in the control group were iv administered with Elemene Injection, 0.6 g Elemene Injection added into 5% glucose solution 500 mL, once daily. The patients in treatment group were iv administered with Xiaoaiping Injection on the basis of control group, 40 mL Xiaoaiping Injection added into 5% glucose solution 250 mL, once daily. The patients in two groups were treated for two courses of treatment, a course of 3 weeks, the next course was progressed after one week of rest. After treatment, the clinical efficacies and the life quality were evaluated, and the changes of CD³⁺, CD⁴⁺, CD⁴⁺/CD⁸⁺, MMP-2, and MMP-9 in two groups were compared before and after treatment. Results After treatment, ORR and CBR in the control group respectively were 43.90% and 75.61%, accordingly 65.85% and 92.68% in the treatment group, and there were differences between two groups (P < 0.05); Improvement rate of survival quality in the control and treatment groups were 80.49% and 95.12%, respectively, and there were differences between two groups (P < 0.05); After treatment, CD³⁺, CD⁴⁺ and CD⁴⁺/CD⁸⁺ were higher than those before treatment, and the difference was statistically significant in the same group (P < 0.05). Compared with the control group, the observational indexes were much better in the treatment group, with significant difference between two groups (P < 0.05); The serum MMP-2 and MMP-9 levels were lower than those before treatment, and the difference was statistically significant in the same group (P < 0.05), but the indexes in treatment group were significantly lower than that in control group, with significant difference between two groups (P < 0.05). Conclusion Xiaoaiping Injection combined with Elemene Injection has good clinical efficacy in the treatment of advanced primary hepatocellular carcinoma, and has high safety, which has a certain clinical application value.